New Year Bumper Sale @ Rs. 1 X
Emnorm 500 Mg Tablet ER is a prescription drug, available for use as Tablet. Primarily, it is used for the treatment of Diabetes.
Medical history of the patient along with age and gender determines the dosage of Emnorm 500 Mg Tablet ER. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. This information has been provided in detail in the dosage section.
Common side effects of Emnorm 500 Mg Tablet ER include Stomach Upset, Difficulty urinating. While these are the most often observed Emnorm 500 Mg Tablet ER side effects, there are can be others also. These have been listed below. Usually, these side effects of Emnorm 500 Mg Tablet ER go away soon, and do not persist beyond the duration of the treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Emnorm 500 Mg Tablet ER's effect during pregnancy is Mild and Moderate while nursing. Further, the section on Emnorm 500 Mg Tablet ER related warnings talks about Emnorm 500 Mg Tablet ER's effects on the liver, heart and kidney.
Emnorm 500 Mg Tablet ER is contraindicated in people with pre-existing medical conditions like Congestive Heart Failure (CHF), Anemia, Shock as it can result in adverse effects. The section on Emnorm 500 Mg Tablet ER contraindications lists all such conditions.
Drug reaction of Emnorm 500 Mg Tablet ER with other medicines has been reported. Refer to the list below for further details.
In addition to these precautions, you may also note that Emnorm 500 Mg Tablet ER is safe while driving, and is is addictive in nature.
Emnorm 500 Mg Tablet ER is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Is the use of Emnorm 500 Mg Tablet ER safe for pregnant women?
Emnorm has mild to no side effects in pregnant women.
Is the use of Emnorm 500 Mg Tablet ER safe during breastfeeding?
Women who are breastfeeding can experience some moderate side effects of Emnorm. Immediately discontinue Emnorm if you observe any side effects. Contact your doctor, and restart using it only if your doctor considers it safe for you.
What is the effect of Emnorm 500 Mg Tablet ER on the Kidneys?
Emnorm is not harmful for kidneys.
What is the effect of Emnorm 500 Mg Tablet ER on the Liver?
Emnorm is not harmful for the liver.
What is the effect of Emnorm 500 Mg Tablet ER on the Heart?
Emnorm is not harmful for the heart.
Emnorm 500 Mg Tablet ER should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Emnorm 500 Mg Tablet ER unless your doctor advises you to do so -
Is this Emnorm 500 Mg Tablet ER habit forming or addictive?
Forming a habit of Emnorm 500 Mg Tablet ER has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
Yes, it is safe to do these activities or work after taking Emnorm 500 Mg Tablet ER as it does not make you drowsy.
Is it safe?
Emnorm 500 Mg Tablet ER should be used only after doctor's advice.
Is it able to treat mental disorders?
Emnorm 500 Mg Tablet ER is unable to treat or cure mental disorders.
Interaction between Food and Emnorm 500 Mg Tablet ER
Information is not available on the interaction of any foods with Emnorm 500 Mg Tablet ER, due to a lack of research on this.
Interaction between Alcohol and Emnorm 500 Mg Tablet ER
Taking Emnorm 500 Mg Tablet ER with alcohol can have severely harmful effects on your health.
Lactic acidosis associated with Emnorm treatment is a rare but fatal adverse effect. Lactic acidosis appears to result from biguanide interference causing an increase in production and decrease in clearance of lactate leading to higher cellular lactate levels. A decrease in pyruvate carboxylase activity, the rate-limiting enzyme in the formation of glucose from lactate, can also decrease hepatic metabolism of lactate. leading to increasing lactic acidosis. Signs and symptoms of Emnorm induced lactic acidosis are nonspecific and include anorexia, nausea, vomiting, altered level of consciousness, hyperpnoea, abdominal pain, and thirst.
Emnorm works by decreasing the hepatic glucose production. It also works to lower blood sugar by increasing your sensitivity to insulin and decreasing the amount of glucose that is absorbed from the food you eat.
Yes, Emnorm commonly cause stomach upset like diarrhea, abdominal pain, nausea, and vomiting. To avoid these side effects you should take Emnorm with your meal and increase the dose gradually.
Emnorm should be taken with food to reduce stomach and bowel side effects, which may experience the first few weeks of treatment. Also, exercise regularly and test for sugar in your blood or urine as directed.
Yes, you can take Emnorm with a beta-blocker. People with diabetes tend to develop heart disease or stroke at an earlier age than the general population. One reason for this is that high glucose levels increase your risk of high blood pressure (hypertension). No harmful interactions are seen between them. However, a recent study suggests that beta-blockers can decrease the plasma level of Emnorm and long-term use can increase lactic acid and uric acid in the blood.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826